Molecular staging and the selection of therapy for non-small cell lung cancer

Semin Thorac Cardiovasc Surg. 2005 Fall;17(3):180-5. doi: 10.1053/j.semtcvs.2005.06.011.

Abstract

The stage-specific selection of therapy is the standard for patients with non-small cell lung cancer. Investigation of the molecular biology of lung cancer has provided pathways and targets that may be used to improve the efficacy of therapy and improve the survival for patients with lung cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Biomarkers, Tumor / analysis
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / therapy
  • Neoplasm Staging
  • Prognosis

Substances

  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • Cyclooxygenase 2 Inhibitors